Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses DNTH in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named DNTH in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Marino Garcia | $630,000 | $0 | $0 | $9,450,952 | $519,750 | $0 | $14,000 | $10,614,702 |
| Director, President and Chief Executive Officer | ||||||||
| Simrat Randhawa | 530,555 | 0 | 0 | 4,288,857 | 388,125 | 0 | 14,000 | 5,221,537 |
| Executive Vice President, Head of Research and Development | ||||||||
| Ryan Savitz | 482,560 | 0 | 0 | 4,288,857 | 289,536 | 0 | 14,000 | 5,074,953 |
| Executive Vice President, Chief Financial Officer, Chief Business Officer and Treasurer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Marino Garcia | $10,614,702 | $8,843,300 | — | +1,771,402 |
| Simrat Randhawa | 5,221,537 | 4,035,266 | — | +1,186,271 |
| Ryan Savitz | 5,074,953 | 4,002,145 | — | +1,072,808 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Ryan Savitz | Option | 115,625 | 22.07 | — |
| Marino Garcia | Option | 143,233 | 17.88 | — |
| Marino Garcia | Option | 112,500 | 39.95 | — |
| Marino Garcia | Option | 146,822 | 21.77 | — |
| Marino Garcia | Option | 262,087 | 22.07 | — |
| Ryan Savitz | Option | 62,500 | 17.88 | — |
| Ryan Savitz | Option | 15,599 | 8.44 | — |
| Ryan Savitz | Option | 60,423 | 21.77 | — |
| Ryan Savitz | Option | 56,250 | 37.87 | — |
| Simrat Randhawa | Option | 7,997 | 8.44 | — |
| Simrat Randhawa | Option | 62,500 | 17.88 | — |
| Simrat Randhawa | Option | 60,423 | 21.77 | — |
| Simrat Randhawa | Option | 115,625 | 22.07 | — |
| Simrat Randhawa | Option | 56,250 | 37.87 | — |
The Company targets a general competitive position, based on independent third-party benchmark analytics, to inform the mix of compensation of base salary, annual incentives, or long-term incentives. The Compensation Committee considers market compensation for comparable positions, historical compensation levels, internal equity, individual performance, and the desire to motivate employees to achieve short- and long-term results in the best interests of stockholders.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-21 | 41,004,507 | 1,713,043 | 500,964 | 95.99% | Passed |
| 2025 | 2025-05-22 | 22,132,031 | 3,684,797 | 9,129 | 85.73% | Passed |
| 2024 | 2024-05-23 | 22,996,759 | 26,822 | 8,360 | 99.88% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-21 | 95.99%a |
| 2025 | 2025-05-22 | 85.73%b |
| 2024 | 2024-05-23 | 99.88%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Sujay KangoIndependent · Compensation · Newly elected | $37,950 | — | $380,910 | — | — | $418,860 |
| Simon ReadIndependent | 30,357 | — | 351,952 | — | — | 382,309 |
| Simon Read, Ph.DIndependent · Nominating and Corporate Governance · Science and Technology | 30,357 | — | 351,952 | — | — | 382,309 |
| Alison F. LawtonIndependent · Board Chair · Audit · Nominating and Corporate Governance (Chair) | 87,311 | — | 172,476 | — | — | 259,787 |
| Anne McGeorgeIndependent · Audit (Chair) · Nominating and Corporate Governance | 59,906 | — | 172,476 | — | — | 232,382 |
| Paula SoteropoulosIndependent · Audit · Compensation (Chair) | 59,311 | — | 172,476 | — | — | 231,787 |
| Steven Romano, M.DIndependent · Compensation · Science and Technology (Chair) | 53,171 | — | 172,476 | — | — | 225,647 |
| Jonathan Violin, Ph.DIndependent · Science and Technology | 45,000 | — | 172,476 | — | — | 217,476 |
| Jonathan ViolinIndependent | 45,000 | — | 172,476 | — | — | 217,476 |
| Leon O. Moulder JrIndependent · Departed during FY | 19,847 | — | 0 | — | — | 19,847 |
| Tomas KiselakIndependent · Departed during FY | 9,303 | — | 0 | — | — | 9,303 |
| Marino GarciaEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 12,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $477,513 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $477,513 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Dianthus Therapeutics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Dianthus Therapeutics.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Stoke Therapeutics, Inc. | 2025 | Ian Smith | $170,625 | $11,590,000 | $14,035,067 | $0 | $27,031,655 |
| 2 | Dianthus Therapeutics | 2025 | Marino Garcia | 630,000 | 0 | 9,450,952 | 519,750 | 10,614,702 |
| 3 | Disc Medicine, Inc. | 2025 | John Quisel | 695,000 | 4,285,817 | 4,441,046 | 554,263 | 9,986,626 |
| 4 | Kymera Therapeutics, Inc. | 2025 | Nello Mainolfi | 693,000 | 0 | 7,318,859 | 519,750 | 8,545,609 |
| 5 | Structure Therapeutics Inc. | 2025 | Raymond Stevens | 672,094 | 2,387,996 | 4,846,926 | 508,871 | 8,429,887 |
| 6 | Vera Therapeutics, Inc. | 2025 | Marshall Fordyce | 660,000 | 2,356,285 | 3,415,725 | 554,400 | 6,986,410 |
| 7 | Spyre Therapeutics, Inc. | 2025 | Cameron Turtle | 665,000 | 0 | 5,552,886 | 475,475 | 6,707,361 |
| 8 | Astria Therapeutics, Inc. | 2024 | Jill Milne | 637,868 | 0 | 5,637,078 | 318,934 | 6,604,416 |
| 9 | Anaptysbio, Inc | 2025 | Daniel Faga | 706,011 | 1,592,001 | 3,345,653 | 465,968 | 6,133,943 |
| 10 | Aura Biosciences, Inc. | 2025 | Elisabet de los Pinos | 645,483 | 1,492,378 | 1,513,293 | 284,013 | 3,956,167 |
| 11 | Annexon, Inc. | 2025 | Douglas Love | 670,833 | 0 | 2,522,260 | 371,250 | 3,579,202 |
| 12 | Inozyme Pharma, Inc. | 2024 | Douglas Treco | 541,667 | 0 | 1,933,375 | 0 | 2,485,392 |
| 13 | Cabaletta Bio, Inc. | 2025 | Steven Nichtberger | 659,550 | 0 | 1,266,978 | 446,982 | 2,401,555 |
| 14 | Dyne Therapeutics, Inc. | 2025 | John Cox | 721,000 | 0 | 937,893 | 410,970 | 2,076,868 |
| 15 | Longboard Pharmaceuticals, Inc. | 2023 | Kevin Lind | 610,000 | 0 | 986,934 | 442,860 | 2,053,804 |
| 16 | 4D Molecular Therapeutics, Inc. | 2025 | David Kirn | 667,252 | 0 | 822,750 | 560,597 | 2,051,343 |
| 17 | Kyverna Therapeutics, Inc. | 2025 | Warner Biddle | 625,000 | 0 | 543,804 | 468,750 | 1,814,980 |
| — | Apogee Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Pepgen Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Edgewise Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Dianthus Therapeutics | not disclosed | Option 100 | not disclosed | Alpine Rewards, LLC |
| 4D Molecular Therapeutics, Inc. | 140% | Options 100 | not disclosed | Radford (part of the Rewards Solutions practice at Aon plc) |
| Anaptysbio, Inc | 110% | not disclosed | No | Alpine Rewards |
| Annexon, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Apogee Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Astria Therapeutics, Inc. | not disclosed | Options 100 | not disclosed | Aon |
| Aura Biosciences, Inc. | not disclosed | not disclosed | not disclosed | Pay Governance |
| Cabaletta Bio, Inc. | 114.49% | Options 100 | not disclosed | Aon |
| Disc Medicine, Inc. | 145% | RSU 50 · Options 50 | not disclosed | Pearl Meyer |
| Dyne Therapeutics, Inc. | 95% | not disclosed | not disclosed | Alpine Rewards, LLC |
| Edgewise Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Inozyme Pharma, Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards |
| Kymera Therapeutics, Inc. | 125% | not disclosed | No | Alpine Rewards |
| Kyverna Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Aon plc |
| Longboard Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Pepgen Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Spyre Therapeutics, Inc. | 130% | Options 100 | not disclosed | Alpine Rewards |
| Stoke Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Structure Therapeutics Inc. | 125% | Options 67 · RSU 33 | No | Aon |
| Vera Therapeutics, Inc. | 140% | RSU 50 · Options 50 | not disclosed | Alpine Rewards |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Marino Garcia | DEF 14A | 2026-04-09 | 0001690585-26-000012 | Section “Executive Compensation”. As printed: 10,614,702. Filing ↗machine: r2 · c25 · span 382326–382336 |
| 2 | Section 01, Simrat Randhawa | DEF 14A | 2026-04-09 | 0001690585-26-000012 | Section “Executive Compensation”. As printed: 5,221,537. Filing ↗machine: r6 · c25 · span 420444–420453 |
| 3 | Section 01, Ryan Savitz | DEF 14A | 2026-04-09 | 0001690585-26-000012 | Section “Executive Compensation”. As printed: 5,074,953. Filing ↗machine: r4 · c25 · span 401356–401365 |
| 4 | Section 08, Sujay Kango | DEF 14A | 2026-04-09 | 0001690585-26-000012 | Section “Director Compensation”. As printed: 418,860. Filing ↗ |
| 5 | Section 08, Simon Read | DEF 14A | 2026-04-09 | 0001690585-26-000012 | Section “Director Compensation”. As printed: 382,309. Filing ↗ |
| 6 | Section 08, Simon Read, Ph.D | DEF 14A | 2026-04-09 | 0001690585-26-000012 | Section “Director Compensation”. As printed: 382,309. Filing ↗ |
| 7 | Section 08, Alison F. Lawton | DEF 14A | 2026-04-09 | 0001690585-26-000012 | Section “Director Compensation”. As printed: 259,787. Filing ↗ |
| 8 | Section 08, Anne McGeorge | DEF 14A | 2026-04-09 | 0001690585-26-000012 | Section “Director Compensation”. As printed: 232,382. Filing ↗ |
| 9 | Section 08, Paula Soteropoulos | DEF 14A | 2026-04-09 | 0001690585-26-000012 | Section “Director Compensation”. As printed: 231,787. Filing ↗ |
| 10 | Section 08, Steven Romano, M.D | DEF 14A | 2026-04-09 | 0001690585-26-000012 | Section “Director Compensation”. As printed: 225,647. Filing ↗ |
| 11 | Section 08, Jonathan Violin, Ph.D | DEF 14A | 2026-04-09 | 0001690585-26-000012 | Section “Director Compensation”. As printed: 217,476. Filing ↗ |
| 12 | Section 08, Jonathan Violin | DEF 14A | 2026-04-09 | 0001690585-26-000012 | Section “Director Compensation”. As printed: 217,476. Filing ↗ |
| 13 | Section 08, Leon O. Moulder Jr | DEF 14A | 2026-04-09 | 0001690585-26-000012 | Section “Director Compensation”. As printed: 19,847. Filing ↗ |
| 14 | Section 08, Tomas Kiselak | DEF 14A | 2026-04-09 | 0001690585-26-000012 | Section “Director Compensation”. As printed: 9,303. Filing ↗ |
| 15 | Section 08, Marino Garcia | DEF 14A | 2026-04-09 | 0001690585-26-000012 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 16 | Section 06, 2026 vote | Form 8-K | 2026-05-22 | 0001690585-26-000026 | Item 5.07 · say-on-pay result. As reported: 95.99% (votes for as printed: 41,004,507). Filing ↗ |
| 17 | Section 06, 2025 vote | Form 8-K | 2025-05-22 | 0000950170-25-076304 | Item 5.07 · say-on-pay result. As reported: 85.73% (votes for as printed: 22,132,031). Filing ↗ |
| 18 | Section 06, 2024 vote | Form 8-K | 2024-05-28 | 0000950170-24-065371 | Item 5.07 · say-on-pay result. As reported: 99.88% (votes for as printed: 22,996,759). Filing ↗ |
| 19 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 20 | Section 09b board cost (computed) | Computed | — | computed | Cash 477,513 + equity 0 + all other 0 = 477,513, summed across the director compensation table rows.machine: formula: Σ = 477,513 |
| 21 | Stoke Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-22 | 0001193125-26-170362 | CEO total compensation as printed in Stoke Therapeutics, Inc.'s own proxy. As printed: 27,031,655. Filing ↗machine: r2 · c31 · span 335841–335851 |
| 22 | Dianthus Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-09 | 0001690585-26-000012 | CEO total compensation as printed in Dianthus Therapeutics's own proxy. As printed: 10,614,702. Filing ↗machine: r2 · c25 · span 382326–382336 |
| 23 | Disc Medicine, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187646 | CEO total compensation as printed in Disc Medicine, Inc.'s own proxy. As printed: 9,986,626. Filing ↗machine: r2 · c29 · span 696477–696486 |
| 24 | Kymera Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191495 | CEO total compensation as printed in Kymera Therapeutics, Inc.'s own proxy. As printed: 8,545,609. Filing ↗machine: r2 · c14 · span 676137–676146 |
| 25 | Structure Therapeutics Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001104659-26-047740 | CEO total compensation as printed in Structure Therapeutics Inc.'s own proxy. As printed: 8,429,887. Filing ↗machine: r1 · c47 · span 552927–552936 |
| 26 | Vera Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-09 | 0001140361-26-014002 | CEO total compensation as printed in Vera Therapeutics, Inc.'s own proxy. As printed: 6,986,410. Filing ↗machine: r2 · c24 · span 581040–581049 |
| 27 | Spyre Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-10 | 0001636282-26-000039 | CEO total compensation as printed in Spyre Therapeutics, Inc.'s own proxy. As printed: 6,707,361. Filing ↗machine: r2 · c48 · span 393018–393027 |
| 28 | Astria Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-28 | 0001104659-25-040180 | CEO total compensation as printed in Astria Therapeutics, Inc.'s own proxy. As printed: 6,604,416. Filing ↗machine: r1 · c35 · span 327451–327460 |
| 29 | Anaptysbio, Inc, Section 10b CEO total | DEF 14A | 2026-06-29 | 0001193125-26-288408 | CEO total compensation as printed in Anaptysbio, Inc's own proxy. As printed: 6,133,943. Filing ↗machine: span 694406–694415 |
| 30 | Aura Biosciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-20 | 0001193125-26-163933 | CEO total compensation as printed in Aura Biosciences, Inc.'s own proxy. As printed: 3,956,167. Filing ↗machine: t10 · r2 · c29 · span 480151–480160 |
| 31 | Annexon, Inc., Section 10b CEO total | DEF 14A | 2026-04-27 | 0001140361-26-017085 | CEO total compensation as printed in Annexon, Inc.'s own proxy. As printed: 3,579,202. Filing ↗machine: r2 · c24 · span 356205–356214 |
| 32 | Inozyme Pharma, Inc., Section 10b CEO total | DEF 14A | 2025-04-29 | 0000950170-25-060198 | CEO total compensation as printed in Inozyme Pharma, Inc.'s own proxy. As printed: 2,485,392. Filing ↗machine: span 345346–345355 |
| 33 | Cabaletta Bio, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-183557 | CEO total compensation as printed in Cabaletta Bio, Inc.'s own proxy. As printed: 2,401,555. Filing ↗ |
| 34 | Dyne Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-173655 | CEO total compensation as printed in Dyne Therapeutics, Inc.'s own proxy. As printed: 2,076,868. Filing ↗machine: r3 · c24 · span 816239–816248 |
| 35 | Longboard Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2024-04-12 | 0000950170-24-044023 | CEO total compensation as printed in Longboard Pharmaceuticals, Inc.'s own proxy. As printed: 2,053,804. Filing ↗machine: r2 · c22 · span 476646–476655 |
| 36 | 4D Molecular Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001140361-26-017427 | CEO total compensation as printed in 4D Molecular Therapeutics, Inc.'s own proxy. As printed: 2,051,343. Filing ↗machine: r2 · c21 · span 356185–356194 |
| 37 | Kyverna Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-13 | 0001193125-26-152835 | CEO total compensation as printed in Kyverna Therapeutics, Inc.'s own proxy. As printed: 1,814,980. Filing ↗machine: r2 · c26 · span 547940–547949 |
| 38 | Section 10a, Structure Therapeutics Inc. reciprocity | DEF 14A | — | 0001104659-26-047740 | Structure Therapeutics Inc.'s most recent proxy was read; its disclosed peer group does not include Dianthus Therapeutics. Filing ↗ |
| 39 | Section 10a, Spyre Therapeutics, Inc. reciprocity | DEF 14A | — | 0001636282-26-000039 | Spyre Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Dianthus Therapeutics. Filing ↗ |
| 40 | Section 10a, Disc Medicine, Inc. reciprocity | DEF 14A | — | 0001193125-26-187646 | Disc Medicine, Inc.'s most recent proxy was read; its disclosed peer group does not include Dianthus Therapeutics. Filing ↗ |
| 41 | Section 10a, Dyne Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-173655 | Dyne Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Dianthus Therapeutics. Filing ↗ |
| 42 | Section 10a, Astria Therapeutics, Inc. reciprocity | DEF 14A | — | 0001104659-25-040180 | Astria Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Dianthus Therapeutics. Filing ↗ |
| 43 | Section 10a, Stoke Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-170362 | Stoke Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Dianthus Therapeutics. Filing ↗ |
| 44 | Section 10a, Anaptysbio, Inc reciprocity | DEF 14A | — | 0001193125-26-288408 | Anaptysbio, Inc's most recent proxy was read; its disclosed peer group does not include Dianthus Therapeutics. Filing ↗ |
| 45 | Section 10a, Vera Therapeutics, Inc. reciprocity | DEF 14A | — | 0001140361-26-014002 | Vera Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Dianthus Therapeutics. Filing ↗ |
| 46 | Section 10a, Kymera Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-191495 | Kymera Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Dianthus Therapeutics. Filing ↗ |